Tag: autoimmunediseases
-
Merck’s $10.8 billion takeover of Prometheus gives it a foothold in immunology
[ad_1] Merck & Co.’s $10.8 billion acquisition of Prometheus Biosciences Inc., which it announced Sunday, is a strategic positive that will help the drug company diversify its portfolio and reduce the risk of an overreliance on its cancer drug Keytruda, analysts said Monday. San Diego, Calif.-based Prometheus RXDX, +69.34% is a clinical-stage biotechnology company focusing…